EBV LMP2A has been associated with nasopharyngeal carcinoma (NPC) [80] and constitutively activates mTOR growth regulatory pathways to mediate cell transformation via PI3K activation (Figure 1), as the PI3K inhibitor Wortmannin specifically blocked Akt phosphorylation in LMP2A-expressing cells [23]. The gene discussed is MTOR; the disease is nasopharyngeal carcinoma.